COOKIE NOTICE

This website sets cookies on your computer, to give you the best experience by personalizing your content and analyzing traffic. Without cookies, the site won’t function as expected. If you want to learn more, please read our Privacy Policy or Cookie Policy.

By closing this message, you consent to the use of cookies on this device.

Intended For US Audiences Only.

HOW IS IT ADMINISTERED?

Like other IVIG treatments, BIVIGAM is given by IV infusion by a medical professional. BIVIGAM can be infused in a doctor’s office, infusion center, or at home. It’s injected into an IV infusion bag and slowly introduced to your body. The infusion typically takes about 4 hours, depending on body size. It may be given more slowly the first time to reduce the risk of side effects.

WHAT IS THE DOSING SCHEDULE?

BIVIGAM is usually given every 3 to 4 weeks. Fewer doses mean more treatment-free days for you! Your healthcare provider may change your dosing schedule, depending on how your body reacts to the medicine.

Icon for body reacting to medication

WHAT IS THE DOSING SCHEDULE?

Layer_1 (3)BIVIGAM is usually given every 3 to 4 weeks. Fewer doses mean more treatment-free days for you! Your healthcare provider may change your dosing schedule, depending on how your body reacts to the medicine.

WHAT ARE THINGS TO DO DURING INFUSIONS?

Review infusion instructions, read books or magazines, listen to music, play games on a device, work on your laptop, or chat with others
Review infusion instructions, read books or magazines, listen to music, play games on a device, work on your laptop, or chat with others
Starting_Review

Review infusion instructions

Starting_Books

Read books or magazines

Starting_Music

Listen to music

Starting_Device

Play games on a device

Starting_Laptop

Work on your laptop

Starting_Chat

Chat with others

Important Safety Information for BIVIGAM®

BIVIGAM is an Immune Globulin Intravenous (Human), 10% Liquid, indicated for the treatment of primary humoral immunodeficiency (PI). This includes, but is not limited to, the humoral immune defect in common variable immunodeficiency (CVID), X linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID).

WARNING: RISK OF BLOOD CLOTS (THROMBOSIS), POOR KIDNEY FUNCTION, AND KIDNEY FAILURE

  • Blood clots may happen with intravenous immune globulin products, including BIVIGAM. Before taking BIVIGAM, talk to your doctor if you:
    • Are of advanced age
    • Are unusually sedentary (long periods of sitting down or inactive)
    • Have a history of blood clots in the veins or arteries, cardiovascular (heart) problems or previous history of stroke
    • Are taking estrogen-containing medicines (birth control pills, hormone replacement therapy)
    • Have a permanent intravenous (IV) catheter
    • Have hyperviscosity (poor blood flow) of the blood (diseases such as multiple myeloma or other causes of elevated proteins in the blood)
  • Kidney problems, kidney failure, and death are more common in people who are taking human immune globulin products, especially those containing sucrose (sugar). BIVIGAM does not contain sucrose. Let your doctor know if you have kidney disease or diseases with kidney involvement, have a history of diabetes, or are older than 65 years of age. Your doctor should check your hydration level, blood infection risk, protein levels, and if you are taking any drugs that may damage your kidneys.
  • If you are at risk for blood clots or kidney problems, your doctor should adjust your starting dose of BIVIGAM and monitor your blood flow.

What is BIVIGAM [Immune Globulin Intravenous (Human), 10% Liquid]?
BIVIGAM [Immune Globulin Intravenous (Human), 10% Liquid] is a prescription medicine to help adults and pediatric patients 2 years of age and older with primary immunodeficiency fight and prevent infections. BIVIGAM is for intravenous administration only. BIVIGAM is made from healthy human blood/plasma.

Who should not use BIVIGAM?
BIVIGAM should not be used if you had a severe allergic reaction to human immune globulin or if you have been told by a doctor that you are immunoglobulin A (IgA) deficient and have developed antibodies to IgA and hypersensitivity after exposure to a previous plasma product.

What are possible warnings and precautions with taking BIVIGAM?
If you take BIVIGAM or a similar immune globulin product, you could experience a serious and life-threatening blood clot (thromboembolism). Thrombosis may occur even if you do not have any risk factors.

Your doctor should perform blood tests to see if you are at risk for poor blood flow (hyperviscosity). These tests will check for the presence of other proteins in the blood that might put you at risk of blood clots.

Kidney problems or failure. Kidney problems, kidney failure, and death may occur with use of human immune globulin products. If your doctor determines that you are at risk of kidney problems, they should monitor your with routine blood and urine tests.

Aseptic meningitis syndrome (AMS). Aseptic meningitis is a non-infectious inflammation of the membranes that cover the brain. It causes a severe headache, which may occur with human immune globulin treatment, including BIVIGAM. AMS usually happens within a few hours to 2 days after treatment. AMS is more commonly associated with higher doses of treatment and/or after rapid infusion. Your doctor may perform a neurological exam, including spinal tap (sampling fluid which surrounds the spinal cord) to evaluate your condition and to rule out other causes of meningitis.

People taking human immune globulin products, including BIVIGAM, may experience hyperproteinemia (high levels of protein in the blood), hyponatremia (low levels of sodium in the blood), and hyperviscosity (poor blood flow). Your doctor may perform certain blood tests and monitor you to minimize any of the above risks.

Hemolysis. Hemolysis refers to the destruction of red blood cells. Immune globulin products, including BIVIGAM, may contain certain antibodies that can result in the rupturing of red blood cells. Your doctor should monitor you for signs and symptoms of hemolysis. People taking human immune globulin products may experience lung-related side effects, including transfusion-related acute lung injury (TRALI). TRALI is a rare but serious syndrome characterized by sudden acute respiratory distress following transfusion. Your doctor should monitor you for lung-related side effects and may conduct tests to check for the presence of certain white blood cells (anti-neutrophils) in the drug or your blood.

Transmissible infectious agents. Because BIVIGAM is made from human blood, it may carry a risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Your doctor will report to the manufacturer any cases of suspected infections spread by the product.

Interference with lab tests. Because BIVIGAM contains a variety of antibodies that are infused into your body, blood tests may provide misleading interpretations. Be sure to tell your doctor, nurse, or lab technician that you are using BIVIGAM.

Interactions with medicines. BIVIGAM can make vaccines (like measles, mumps, rubella, and chicken pox vaccines) less effective in your body. Before you get any vaccines, tell your healthcare provider that you take BIVIGAM.

What are other possible side effects of BIVIGAM?

In clinical studies of BIVIGAM, some patients experienced the following serious side effects:

  • Vomiting
  • Dehydration

The most common side effects included:

  • Headache
  • Fatigue
  • Reaction at the site of infusion
  • Nausea
  • Sinus inflammation (sinusitis)
  • Blood pressure increase
  • Diarrhea
  • Dizziness
  • Loss of energy (lethargy)

These are not all the possible side effects of BIVIGAM. Talk to your healthcare provider about any side effect that bothers you or that does not go away.

You are encouraged to report side effects of prescription drugs to ADMA Biologics at 1-800-458-4244 or the FDA. Visit www.fda.gov/medWatch or call 1-800-FDA-1088.

For more information about BIVIGAM, please see full Prescribing Information.

The information on this site is intended for audiences in the United States only. The content on this site may not apply to non-US audiences as regulatory control, legal requirements, and/or medical practices may vary in other countries.

© 2023 ADMA Biologics, Inc. All rights reserved. BIVIGAM® is a registered trademark of ADMA Biologics, Inc. ADvantage Ig™ is a trademark of ADMA Biologics, Inc. PARTNER IN PROTECTION™ is a trademark of ADMA Biologics, Inc.